Prevalence of Subclinical Hypothyroidism in Pregnancy and Its Association With Anti-thyroperoxidase Antibody and the Occurrence of Gestational Diabetes Mellitus

Prakruti Dash 1, Rajlaxmi Tiwari 2, Saurav Nayak 1, Saubhagy K. Jena 3, Manaswini Mangaraj 1

1. Biochemistry, All India Institute of Medical Sciences, Bhubaneswar, Bhubaneswar, IND 2. Biochemistry, Institute of Medical Sciences and SUM Hospital, Bhubaneswar, IND 3. Obstetrics and Gynecology, All India Institute of Medical Sciences, Bhubaneswar, Bhubaneswar, IND

Abstract

Introduction

Subclinical hypothyroidism (SCH) and gestational diabetes mellitus (GDM) are common endocrinological abnormalities associated with pregnancy. The presence of a raised anti-thyroperoxidase (anti-TPO) antibody titer increases the risk of progression of subclinical hypothyroidism to overt hypothyroidism. Subclinical hypothyroidism and GDM are known to affect maternal and fetal outcomes adversely. A few studies have shown an increased risk of GDM with autoimmune hypothyroidism. However, data regarding this association between GDM, SCH, and anti-TPO Ab are scarce. This study aimed to find the prevalence of autoimmune subclinical hypothyroidism and its association with GDM in pregnancy.

Materials and methods

In a cross-sectional study, 382 pregnant women at their first antenatal checkup (ANC) were enrolled in the study. Serum thyroid-stimulating hormone (TSH), free T4 (FT4), anti-TPO Ab, and the 75 g oral glucose tolerance test (OGTT) were evaluated. The results obtained were analyzed in Systat Version 13.2 (SPSS Inc., Chicago, IL).

Observations

Results showed an SCH prevalence of 37.69% with a raised anti-TPO Ab titer in 49.31% of the diagnosed SCH cases, pointing towards an autoimmune etiology. Our study revealed a GDM prevalence of 12.04%. Out of the 46 GDM cases, 16 were found to have SCH and 3 cases had raised anti-TPO Ab titers. In our study, 27.73% of euthyroid pregnant women had a raised anti-TPO Ab titer. Our study revealed no significant association between GDM, SCH, and raised anti-TPO Ab titer.

Conclusion

Anti-TPO antibody subsequently leads to hypothyroxinemia, for which it is necessary that cases with high titer of anti-TPO antibody though euthyroid should be meticulously followed up and screened for to detect development of hypothyroidism or SCH, particularly in future pregnancies. However, GDM prevalence was at par with the national figure, but with no significant association of SCH and a high anti-TPO Ab titer was found with GDM in our study. Further studies with a larger cohort may establish a causal association between the two most common endocrinological disorders observed in pregnancy.
growth and development of children in the long run [12]. In several studies, repercussions of abnormal thyroid hormone status have also been noted on the villous and extra-villous trophoblastic proliferation, affecting the viability of the placenta [13,14].

The incidence of hypothyroidism in pregnancy is higher in Asian countries, with more observed in the Indian population being attributed to nutritional as well as immunological origins. Even subclinical hypothyroidism (SCH) with high thyroid-stimulating hormone (TSH) and a normal thyroxine level is commonly associated with endocrine abnormalities in pregnancy [15-19]. Anti-thyroglobulin (anti-TPO) antibody having the ability to cross the placenta has been suggested to affect fetal growth [20,21]. Euthyroid pregnant women with high anti-TPO antibody titers have been registered with several adversities in obstetric and fetal outcomes [22-24].

Gestational diabetes mellitus (GDM) is a frequent occurrence in the second trimester of pregnancy, with the risk being greater with increasing age [25-27]. Autoimmune diseases like insulin-dependent diabetes mellitus (IDDM), Hashimoto’s thyroiditis, pernicious anemia, etc., are more common in women and occur concomitantly. An association between hypothyroidism and different types of diabetes mellitus has been reported previously [28-30].

Various studies have documented beta-cell dysfunction and insulin resistance as the basis of the development of GDM [31]. Inflammatory events associated with autoimmune disorders and insulin resistance are suggested to be the potential link between the two conditions. Insulin resistance was found to be associated with autoimmune thyroid dysfunction with a raised titer of anti-TPO antibodies, signifying a possible relationship between autoimmune thyroid dysfunction and GDM. Some studies have documented an increased risk of GDM with hypothyroidism and a raised titer of anti-TPO Ab [32-35], whereas some others have registered no significant association between GDM and autoimmune thyroid disorders in pregnancy [36,37]. Yang et al. in their meta-analysis showed that there was a significant but not strong association between thyroid antibodies and the risk of GDM [38].

Moreover, data regarding the prevalence of hypothyroidism and autoimmunity in women with GDM are scarce. Hence, the following study was conducted in a tertiary care center to estimate the prevalence of subclinical hypothyroidism in pregnant women, its association with raised anti-TPO antibody titer, and the occurrence of GDM detected at their first antenatal visit.

**Materials And Methods**

This cross-sectional study was conducted in the Department of Biochemistry, in collaboration with the Department of Obstetrics and Gynecology, and 382 eligible pregnant women coming for their first antenatal checkup (ANC) were enrolled in the study.

Apparent health pregnant women, both primigravida and multi-gravida, with singleton pregnancies in their first ANC were included and written informed consent was obtained from the enrolled cases. Pregnant women with preexisting thyroid diseases or any other endocrine disorders, pre-existing diabetes, on any hormone replacement therapy, any other metabolic or chronic disorders, and bad obstetric history with a known cause were excluded from the study.

After general and gynecological examination, fasting, one-hour, and two-hour blood samples were collected for 75 g OGTT and estimation of thyroid profile (TSH, fT4, anti-TPO antibody). The biochemical parameters were performed on the Beckman Coulter AU5A00 auto analyzer with commercially available kits. Thyroid profiles were done by the chemiluminescence method in an Siemens Advia Centaur automated Immunoassay analyzer.

For this study, the trimester-specific upper limit value for TSH was taken as <2.5 mIU/mL for the first trimester and <3 mIU/mL for the second and third trimesters as per American Thyroid Association (ATA) 2011 criteria. Patients with TSH levels higher than the trimester specific level and normal fT4 levels were diagnosed with SCH. Anti-TPO level <60 U/L was taken as normal upper limit as per manufacturer’s protocol. Level more than 60U/L is considered a raised anti-TPO titer.

GDM was diagnosed using 75 g of glucose challenge test (GCT) with a fasting value of more than 92 mg/dl, a one-hour post-glucose value of more than 180 mg/dl, and a two-hour post-glucose value of more than 155 mg/dl.

The study has got ethical clearance from the Institute Ethics Committee.

The results obtained were statistically analyzed with Systat Version 13.2 (SPSS Inc., Chicago, IL). The normality distribution of the data was assessed by the Shapiro-Wilk test. Data were presented as a median value. One-way analysis of variance (ANOVA) was put in to see the significance. A p-value of <0.05 was considered to be statistically significant.
Results

The number of pregnant women screened was 382 at a gestational age of between 11 and 34 weeks, with a median of 25 weeks. The prevalence of SCH in pregnancy in our study was found to be 37.69% (144 out of 382 study participants). The presence of a raised anti-TPO Ab titer was seen in 49.31% of SCH cases, indicating an autoimmune etiology. The prevalence of GDM was 12.04% (46 out of 382 study participants) in our study, and the number of cases associated with SCH was seen to be 34.7% (16 cases), and both SCH and raised anti-TPO Ab titer were observed in three cases (6.5%). Thirty cases (65.1%) of GDM were euthyroid and out of those, four (8.5%) cases were found to have raised anti-TPO Ab titer (Figure 1).

![Prevalence of SCH, GDM, and raised anti-TPO antibody titre in the study population](image)

**FIGURE 1: Prevalence of SCH, GDM, and raised anti-TPO antibody titer in the study population**

SCH: subclinical hypothyroidism, GDM: gestational diabetes mellitus, TPO: thyroperoxidase antibody

The serum TSH value was highest in cases with a raised anti-TPO Ab titer that was statistically significant (p<0.01). We observed that the data were not normally distributed as the normality test (Shapiro-Wilk) had a p-value of ≤0.001. As a result, all of the data are represented as median (IQR), and a one way ANOVA was performed to determine significance (Table 1).

| Sl. No. | Parameter | Controls (SCH absent N = 238 median (IQR)) | SCH+/ATPO+N = 71 median (IQR) | SCH+/ATPO−N = 73 median (IQR) | One way ANOVA (p-value) |
|---------|-----------|---------------------------------------------|--------------------------------|--------------------------------|-------------------------|
| 1       | TSH mIU/mL | 1.575 (1.19–1.992)                          | 3.84 (3.075–4.605)            | 3.37 (2.95–4.5)               | ≤0.001*                 |
| 2       | FT4 ng/dL  | 1.145 (1–1.3)                               | 1.1 (0.995–1.235)             | 1.17 (1.1–1.3)                | 0.076                   |
| 3       | Anti-TPO Ab U/L | 44.9 (29.35–60.075) | 110 (77.9–201.5) | 35.5 (28–44) | ≤0.001* |
| 4       | 75 g GCT FBS in mg% | 90 (84–117) | 102 (85.5 120.5) | 99 (65 – 106) | 0.630 |
| 5       | 75 g GCT 1 hour PGBS in mg% | 132 (100–165) | 160 (110–200) | 148 (110–172) | 0.670 |
| 6       | 75 g GCT 2 hour PGBS in mg% | 110 (98–124) | 146 (100–189) | 134 (100–186) | 0.754 |

**TABLE 1: Median value and range of the study parameters**

TSH: thyroid stimulating hormone, SCH: subclinical hypothyroidism, ATPO: anti-thyroperoxidase, FT4: free thyroxine, GCT: glucose challenge test, FBS: fasting blood sugar, PGBS: post-glucose blood sugar

Table 2 represents the number of SCH cases showing a raised anti-TPO Ab titer (>60 U/L). Seventy-one out
of 144 pregnant women with SCH in our study had a raised anti-TPO Ab titer in their serum. Similarly, 27.73% (66 out of 282) of the study participants with euthyroid status showed a raised anti-TPO Ab titer in their serum.

| Total n=382 | Anti-TPO antibody titer >60 U/L | Anti TPO antibody titer <60 U/L |
|-------------|---------------------------------|--------------------------------|
| Euthyroid N=238 | 66 (27.73%)                      | 172 (72.2%)                    |
| SCH N=144  | 71 (49.31%)                      | 73 (50.69%)                    |

**TABLE 2: Anti-TPO antibody titer in the study population**

Anti-TPO: anti-thyroperoxidase, SCH: subclinical hypothyroidism, U/L: units/liter

We observed that GDM had a prevalence of 12.04% (46 cases out of 382 participants) in the study population. Out of the 46 cases, 16 had both GDM and SCH, and 3 of them were observed to have raised anti-TPO Ab along with SCH and GDM. Of the 30 euthyroid cases diagnosed with GDM, four participants had a raised anti-TPO Ab titer in their serum (Table 3).

| Group | Anti-TPO titer >60U/L | Anti-TPO titer <60U/L |
|-------|-----------------------|-----------------------|
| Total GDM cases n=46 (12.04%) | 03 (6.5%) | 13 (28.2%) |
| GDM with SCH (n=16) | 03 (6.5%) | 13 (28.2%) |
| GDM with euthyroid (n=30) | 4 (8.6%) | 26 (56.5%) |

**TABLE 3: Prevalence of GDM with SCH and raised ATPO antibody titer in the study population**

GDM: gestational diabetes mellitus, SCH: subclinical hypothyroidism, ATPO: anti-thyroperoxidase antibody

In our study, we could not find any increased risk of GDM associated with SCH and raised anti-TPO Ab titer in the study population (Table 4).

| Sl. No. | Comparison                     | RR  | p-Value |
|---------|-------------------------------|-----|---------|
| 1       | SCH with ATPO positive vs SCH with ATPO negative | 0.996 | 1.000  |
| 2       | SCH with ATPO positive vs euthyroid | 1.010 | 0.836  |
| 3       | SCH with ATPO negative vs euthyroid | 1.006 | 0.839  |

**TABLE 4: Relative risk of GDM compared with SCH with ATPO positive vs SCH with ATPO negative vs controls (no SCH)**

GDM: gestational diabetes mellitus, SCH: subclinical hypothyroidism, ATPO: anti-thyroperoxidase antibody, RR: relative risk

**Discussion**

This study was aimed at evaluating the prevalence of subclinical hypothyroidism during pregnancy in a tertiary-level hospital in Eastern India. The occurrence of raised anti-TPO Ab titer and association of GDM with SCH and raised anti-TPO Ab titer were also evaluated compared to euthyroid cases.

Globally, the prevalence of hypothyroidism in pregnant women is reported to be extremely variable [39]. In India, reports on the prevalence of hypothyroidism in pregnancy range from 1.2% to more than 60% in several studies. In a meta-analysis of 61 studies across 60,066 study subjects by Yadav et al., the prevalence of overt hypothyroidism in India was documented to be 11.07% [40].
The prevalence of SCH in pregnancy differs extensively worldwide [41]. In India, the prevalence of SCH varies from 2.8% to 32.94% in different parts of the country, as documented in various studies [42-45].

Gayathri et al. reported the prevalence of SCH of 2.8% among pregnant women in Chennai and 57.1% of the subclinical hypothyroid patients had positive TPO antibodies [42]. Aggarwal et al. documented the prevalence of SCH to be 10.9% among pregnant women in a study conducted in a premier institute in north India, and TPO antibody positivity was 59% among the subclinical hypothyroid pregnant women in their study [43]. Another study conducted in Delhi by Dhanwal et al. has cited an even higher prevalence of SCH (15.8%) among pregnant women and a good number (57%) of them were TPO antibody positive [44]. All the studies mentioned above used a cut-off value of TSH >4.5 μIU/ml to diagnose SCH.

In a study by Mandal et al., 32.94% of the pregnant mothers had subclinical hypothyroidism and anti-TPO Ab positivity was found in 12.15% of the study population and in 33.95% of the SCH pregnant women [45]. Thus, it is evident that the prevalence of SCH varies widely in different parts of the country among pregnant women.

In our study, we documented a comparatively higher prevalence of subclinical hypothyroidism, i.e., 57.69%, which is quite high compared to other studies but almost in accordance with Mandal et al. as we used ATA 2011 criteria with an upper limit of TSH of 2.5 mIU/L in the first trimester and 5 mIU/L in the second and third trimesters.

In the overall study population of our study, 49.31% of SCH cases were found to have anti-TPO positivity in their serum. Compared to studies done by Gayathri et al., Aggarwal et al., and Dhanwal et al. [42-44], the percentage of SCH cases having anti-TPO antibody positivity was lower in our study population. This may be attributed to iodine deficiency as the most common cause of lower levels of thyroid hormones and autoimmunity coming next to it in our geographical distribution.

The prevalence of SCH in pregnancies in our study and the raised level of anti-TPO antibody titer observed in euthyroid subjects may give an alarm and reinforce the need for regular and mandatory screening of thyroid hormone status in pregnancy along with screening for anti-TPO Ab. Women with euthyroid status but with raised anti-TPO Ab positivity should ideally be followed up for more rigorous assessment of hypothyroidism in subsequent pregnancies.

The prevalence of GDM in our study was found to be 12.04%. GDM coexisted with SCH in 16 study participants. Out of the 16 cases of GDM with SCH, 3 cases were observed to have raised anti-TPO titers. Similarly, among the 30 GDM cases with euthyroid status, 4 cases were found to have raised anti-TPO Ab titers.

The prevalence of GDM in India, as per current statistics, varies from 4% to 18%. Literature also shows the prevalence rate is higher in urban areas than in rural areas. Our study population was heterogenous in geographical and social distribution. We observed a prevalence rate of 12.04%, which is in accordance with the documented data [25,26].

Many authors [46, 47] have reported the occurrence of hypothyroidism and raised anti-TPO Ab titers amongst women with GDM. Many studies have documented an increased risk of GDM in hypothyroidism associated with high anti-TPO Ab titers during pregnancy [48-51]. In our study, however, we found no statistically significant association between GDM, SCH, and high anti-TPO antibody titer.

Relative risk assessment of GDM in association with SCH and raised anti-TPO Ab titer versus SCH with normal anti-TPO Ab titer versus euthyroid revealed no statistically significant value.

**Conclusions**

The present study revealed an increase in subclinical hypothyroidism in pregnancy in our geographical area. A significant number of SCH with high anti-TPO antibody titer points towards autoimmunity as being a significant cause of the decreased level of thyroid hormones in pregnancy. However, GDM prevalence was at par with the national figure but with no significant association of SCH, and a high anti-TPO ab titer was found with GDM in our study.

Further longitudinal studies with a larger cohort may establish a causal association between the two most common endocrine disorders observed in pregnancy. Looking at the adverse impact of hypothyroidism on pregnancy outcomes as registered by various studies, mandatory screening for thyroid status in pregnancy has been approved by various regulatory bodies and is now in practice. However, screening for autoimmunity with measurement of anti-TPO ab titer is currently not done regularly. As anti-TPO antibody subsequently leads to hypothyroxinemia as per documented reports, it is necessary that cases with a high titer of anti-TPO antibody though euthyroid particularly in primigravida cases should be meticulously followed up and screened for to detect the development of hypothyroidism or SCH, particularly in future pregnancies.
Undiagnosed thyroid dysfunction and autoimmunity might potentially amplify the maternal and fetal complications associated with hypothyroxinemia.

**Additional Information**

**Disclosures**

**Human subjects:** Consent was obtained or waived by all participants in this study. Institutional Ethics Committee, All India Institute of Medical Sciences, AIIMS Bhubaneswar issued approval ECR/534/Inst/OD/2014. IEC Approval Number: T/IM-F/Biochem/15-1.Dt :02/05/16. **Animal subjects:** All authors have confirmed that this study did not involve animal subjects or tissue. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**References**

1. Glinzer D, de Nayer P, Bourdoux P, et al.: Regulation of maternal thyroid during pregnancy. J Clin Endocrinol Metab. 1990, 71:276-87. 10.1210/jem-71-2-276
2. Talat A, Khan AA, Naseer S, Wasi A: Thyroid screening during early pregnancy and the need for trimester specific reference ranges: a cross-sectional study in Lahore, Pakistan. Cureus. 2019, 11:e5661. 10.7759/cureus.5661
3. Kwakkel J, Surovtseva OV, de Vries EM, Stap J, Fliers E, Boelen A: A novel role for the thyroid hormone-activating enzyme type 2 deiodinase in the inflammatory response of macrophages. Endocrinology. 2014, 155:2725-34. 10.1210/en.2013-2066
4. Yoshimura M, Hershman JM: Thyrotropic action of human chorionic gonadotropin. Thyroid. 1995, 5:425-34. 10.1089/thy.1995.5.425
5. Utiger RD: Maternal hypothyroidism and fetal development. N Engl J Med. 1999, 341:601-2. 10.1056/NEJM199908183410801
6. Banovac K, Ryan EA, O’Sullivan MJ: Triiodothyronine (T3) nuclear binding sites in human placenta and decidua. Placenta. 1986, 6:545-54. 10.1016/0143-4004(86)80140-0
7. Fisher DA: Thyroid function in very low birthweight infants. Clin Endocrinol (Oxf). 1997, 47:419-21. 10.1046/j.1365-2265.1997.02110.x
8. Casey BM, Dashe JS, Wells CE, et al.: Subclinical hypothyroidism and pregnancy outcomes. Obstet Gynecol. 2005, 106:198-199. 10.1097/01.ogc.0000169597.61122.be
9. Leung AS, Millar LK, Koonsings PP, Montoro M, Mestman JH: Perinatal outcome in hypothyroid pregnancies. Int J Obstet Gynecol. 1995, 43:230-3. 10.1016/0020-7292(95)90543-u
10. Kilby MD, Verhaeg J, Gittoes N, Somerset DA, Clark PM, Franklyn JA: Circulating thyroid hormone concentrations and placental thyroid hormone receptor expression in normal human pregnancy and pregnancy complicated by intrauterine growth restriction (IUGR). J Clin Endocrinol Metab. 1998, 83:2964-71. 10.1210/jcem.83.8.5002
11. Shields BM, Knight RA, Hill A, Hattersley AT, Vaidya B: Fetal thyroid hormone level at birth is associated with fetal growth. J Clin Endocrinol Metab. 2011, 96:E954-8. 10.1210/jc.2010-2814
12. Haddow JE, Palomaki GE, Allan WC, et al.: Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med. 1999, 341:549-55. 10.1056/NEJM199908183410801
13. Oki N, Matsuo H, Nakago S, Murakoshi H, Laoag-Fernandez JB, Maruo T: Effects of 5,5',5'-triiodothyronine on the invasive potential and the expression of integrins and matrix metalloproteinases in cultured early placental extravillous trophoblasts. J Clin Endocrinol Metab. 2004, 89:5215-21. 10.1210/jc.2004-0332
14. Barber KJ, Franklyn JA, McCabe CJ, Khanim FL, Bulmer JW, Whiteley GS, Kilby MD: The in vitro effects of triiodothyronine on epidermal growth factor-induced trophoblast function. J Clin Endocrinol Metab. 2005, 90:1655-61. 10.1210/jc.2004-0785
15. Nambar V, Jagtap VS, Sarathi V, et al.: Prevalence and impact of thyroid disorders on maternal outcome in asian-Indian pregnant women. J Thyroid Res. 2011, 2011:429097. 10.4061/2011/429097
16. Saha MT, Das V, Mittal S, Agarwal A, Sahu M: Overt and subclinical thyroid dysfunction among Indian pregnant women and its effect on maternal and fetal outcome. Arch Gynecol Obstet. 2010, 281:215-20. 10.1007/s00404-009-1105-1
17. Dhanwal DK, Prasad S, Agarwal AK, Dixit V, Banerjee AK: High prevalence of subclinical hypothyroidism during first trimester of pregnancy in North India. Indian J Endocrinol Metab. 2013, 17:281-4. 10.4103/2230-8210.109712
18. Ajmani SN, Aggarwal D, Bhatia P, Sharma M, Sarabhai V, Paul M: Prevalence of overt and subclinical thyroid dysfunction among pregnant women and its effect on maternal and fetal outcome. Iran J Gynecol. 2014, 64:105-10. 10.15224/105-0485p-1
19. Murtu N, Uma B, Rao JM, et al.: High prevalence of subclinical hypothyroidism in pregnant women in South India. JRCOG. 2015, 4:455. 10.1545/jrcog.20150433
20. Balucan FS, Morshed SA, Davies TF: Thyroid autoantibodies in pregnancy: their role, regulation and clinical relevance. J Thyroid Res. 2015, 2015:182472. 10.1155/2015/182472
21. Seror J, Amand G, Guibaudenche J, Ceccaldi PF, Luton D: Anti-TPO antibodies diffusion through the placental barrier during pregnancy. PLoS One. 2014, 9:e84647. 10.1371/journal.pone.0084647
22. Ghasabian A, Borgers-Schokking H, de Rijke YB, et al.: Maternal thyroid autoimmunity during pregnancy.
and the risk of attention deficit/hyperactivity problems in children: the Generation R Study. Thyroid. 2012, 22:178-86. 10.1097/tyh.2011.0318

23. Stagnaro-Green A: Thyroid antibodies and miscarriage: where are we at a generation later? J Thyroid Res. 2011, 2011:941949. 10.4061/2011/941949

24. Männistö T, Vääräsmäki M, Pouta A, et al.: Thyroid dysfunction and autoantibodies during pregnancy as predictive factors of pregnancy complications and maternal morbidity in later life. J Clin Endocrinol Metab. 2010, 95:1084-94. 10.1210/jc.2009-1904

25. Swaminathan G, Swaminathan A, Corsi DJ: Prevalence of gestational diabetes in India by individual socioeconomic, demographic, and clinical factors. JAMA Netw Open. 2020, 3:e2025074. 10.1001/jamanetworkopen.2020.25074

26. Seshiah V, Balaji V, Balaji MG, Paneerelvela V, Arthi T, Thamizharasi M, Datta M: Gestational diabetes mellitus manifests in all trimesters of pregnancy. Diabetes Res Clin Pract. 2007, 77:482-4. 10.1016/j.diabres.2007.01.001

27. Su FL, Lu MC, Yu SC, Yang CP, Yang CC, Tseng ST, Yan YH: Increasing trend in the prevalence of gestational diabetes mellitus in Taiwan. J Diabetes Investig. 2021, 12:2080-8. 10.1111/jdi.13595

28. Bech K, Heier-Madsen M, Feldt-Rasmussen U, Jensen BM, Melsted-Pedersen L, Kühl C: Thyroid function and autoimmune manifestations in insulin-dependent diabetes mellitus during and after pregnancy. Acta Endocrinol (Copen). 1991, 124:554-9. 10.1530/acta.1240554

29. Alvarez-Marfany M, Roman SH, Drexler AJ, Robertson C, Stagnaro-Green A: Long-term prospective study of postpartum thyroid dysfunction in women with insulin dependent diabetes mellitus. J Clin Endocrinol Metab. 1994, 79:10-16. 10.1207/s1552813xjem7901012

30. Weetman AP: Insulin-dependent diabetes mellitus and postpartum thyroiditis: an important association. J Clin Endocrinol Metab. 1994, 79:7-9. 10.1207/s1552813xjem7901013

31. Catalano PM: Trying to understand gestational diabetes. Diabet Med. 2014, 51:275-81. 10.1111/dme.12581

32. Bitterman O, Bongiovanni M, Giuliani C, Roma G, Toccano V, Napoli A: Anti thyroperoxidase and anti-thyroglobulin antibodies in diabetic pregnancies. J Endocrinol Invest. 2014, 37:911-5. 10.1007/s40618-014-0087-4

33. Nemani S, Kurumeti VK: Prevalence of thyroid dysfunction and autoimmunity among pregnant women with gestational diabetes mellitus in a tertiary care hospital, Visakapattanam. IJRCOG. 2020, 9:4621.

34. Oliveri A, Valensise H, Magrini F, et al.: High frequency of antithyroid autoantibodies in pregnant women at increased risk of gestational diabetes mellitus. Eur J Endocrinol. 2000, 143:741-7. 10.1502/eje.1.450741

35. Agarwal MM, Dhatt GS, Punisse J, Bishawi B, Zayed R: Thyroid function abnormalities and antithyroid antibody prevalence in pregnant women at high risk for gestational diabetes mellitus. Gynecol Endocrinol. 2006, 22:261-6. 10.1080/09513590600630470

36. Xu C, Zhang Z: Comparative study of thyroid hormone and antithyroid antibody levels in patients with gestational diabetes mellitus and pregnant patients with diabetes. Minerva Endocrin. 2018, 43:126-30. 10.23736/s0391-1977.1977.012256-8

37. Montaner P, Juan L, Campos R, Gil L, Corcayo R: Is thyroid autoimmunity associated with gestational diabetes mellitus?. Metabolism. 2008, 57:522-5. 10.1016/j.metabol.2007.11.015

38. Yang Y, Li Q, Wang Q, Ma X: Thyroid antibodies and gestational diabetes mellitus: a meta-analysis. Fertil Steril. 2015, 104:665-71.e5. 10.1016/j.fertnstert.2015.06.003

39. Hennessy JV, Espallat R: Subclinical hypothyroidism: a historical view and shifting prevalence. Int J Clin Pract. 2015, 69:771-82. 10.1111/iicp.12619

40. Yadav V, Dahar D, Goel AD, et al.: Prevalence of hypothyroidism in pregnant women in India: a meta-analysis of observational studies. J Thyroid Res. 2021, 2021:5515831. 10.1155/2021/5515831

41. Klein RZ, Haddow JE, Faix J, Brown RS, Hermos RJ, Pulkkinen A, Mitchell ML: Prevalence of thyroid deficiency in pregnant women. Clin Endocrinol (Oxf). 1991, 35:41-6. 10.1111/j.1365-2265.1991.tb05494.x

42. Rayathri R, Lavanya S, Ravaghan K: Subclinical hypothyroidism and autoimmune thyroiditis in pregnancy—a study in south Indian subjects. J Assoc Physicians India. 2009, 57:691-5.

43. Aggarwal N, Suri V, Joshi B, Dutta P, Bhanjali A, Mukhopadhyay K: Prevalence and impact of subclinical hypothyroidism on pregnancy—prospective study from apex institute of North India. Indian J Appl Res. 2014, 4:404-4. 10.3126/ijar.2014.22541

44. Dhanwal DK, Balaji S, Rajput R, et al.: Prevalence of hypothyroidism in pregnancy: an epidemiological study from 11 cities in 9 states of India. Indian J Endocrinol Metab. 2016, 20:387-90. 10.4103/2230-8210.175992

45. Mandal BC, Bhardwaj D, Das A, Basu S, Kundu SB, Mahapatra C: Subclinical hypothyroidism in pregnancy: an emerging problem in Southern West Bengal: a cross-sectional study. J Nat Sci Biol Med. 2016, 7:308-4. 10.4103/0976-9667.175880

46. Fatima SS, Rehman R, Butt Z, Asif Tauni M, Fatima Munim T, Chaudhry B, Khan TA: Screening of subclinical hypothyroidism during gestational diabetes in Pakistani population. J Matern Fetal Neonatal Med. 2016, 29:2166-70. 10.3109/14767058.2015.1077515

47. Tadela CM, Casey BM, Mcintire DD, Cunningham FG: Relationship of subclinical thyroid disease to the incidence of gestational diabetes. Obstet Gynecol. 2012, 119:983-8. 10.1097/ago.0b013e3182502ae9b

48. Sert UY, Buyuk GN, Engin Ustun Y, Orga Erdinc AS: Is there any relationship between thyroid function abnormalities, thyroid antibodies and development of gestational diabetes mellitus (GDM) in pregnant women?. Medeni Med J. 2020, 55:195-201. 10.5222/mmj.2020.29964

49. Maleki N, Tavosi Z: Evaluation of thyroid dysfunction and autoimmunity in gestational diabetes mellitus and its relationship with postpartum thyroiditis. Diabet Med. 2015, 52:206-12. 10.1111/dme.12580

50. Konar H, Sarker M, Roy M: Association of thyroid dysfunction and autoimmunity in pregnant women with diabetes mellitus. J Obstet Gynaecol India. 2018, 68:283-8. 10.1007/s40624-017-1035-0

51. Karakosta P, Alegakis D, Georgiou V, et al.: Thyroid dysfunction and autoantibodies in early pregnancy are associated with increased risk of gestational diabetes and adverse birth outcomes. J Clin Endocrinol Metab. 2012, 97:4464-72. 10.1210/jc.2012-2540